Emerging treatments

Gabapentin

One randomised, double-blind trial found that gabapentin significantly improved cough-specific quality of life compared with placebo.[36]​ Gabapentin has been advocated in the management of chronic cough, but clinical experience suggests that its use may be limited by adverse effects.[31][32]​​​

Gefapixant

Gefapixant, an oral P2X3 receptor antagonist, significantly reduced 24-hour cough frequency compared with placebo (at 12 and 24 weeks) in two double-blind, randomised, parallel-group studies of patients with refractory chronic cough or unexplained chronic cough.[37][38]​​

Use of this content is subject to our disclaimer